Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
TRAWS PHARMA INC (TRAW)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.22-18.06%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for TRAW yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Successfully deploy $15.8M raised in private placement | A supporting condition in TRAWS PHARMA INC's published investment case. The stated target is deploy $15.8M effectively. | Intact | capital raised is insufficient or misallocated causing operational setbacks | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
TRAW is a high-risk, loss-making early-stage healthcare company, not an established earnings compounder. Its long-term thesis is on watch: recent signals improved from mixed to mildly favorable, but execution quality remains fragile and management has been volatile.
The valuation evidence suggests TRAW is cheap versus peers, but confidence in that comparison is low. The priced-in assessment calls the fragility justified, with low fragility concentration; it does not suggest that the market has fully priced away the business risks.
Near term, private placement proceeds have lifted cash to $5.0 million, and management expects the funds to support operations into Q1 2027. Hantavirus treatment development is still early, with no specific financial measures or clinical milestones reported. A guidance cut is a meaningful risk at the next call, while recent performance remains below the industry cohort despite an August earnings beat.
The multi-year thesis hinges on whether management turns financing into clinical progress and sustains operations beyond the stated runway. Near term, guidance and the jobs trend are key risks, while continued strength from healthcare bellwethers could support sector momentum.
Over the next one to three years, TRAW remains a speculative, loss-making company with some added funding and early clinical work, but limited proof of durable execution. The thesis depends on progress in development and financing, with meaningful near-term reporting and economic risks. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The company aims to improve its financial performance from a net loss of $7.1 million in Q1 2026. |
| Improving |
| net losses worsen beyond -$7.1M over next 4 quarters |
Net income: $-3.054M FY2026-Q2; GAAP. Published target: net loss less negative than -$7.1M. Target period is not explicitly aligned with this observation. Aug 14, 2026-3,054,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Achieve ~100% revenue growth by FY27 | A primary condition in TRAWS PHARMA INC's published investment case. The stated target is >=100% YoY revenue growth. | Intact | YoY revenue growth falls below ~100% in FY27 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.27 → $-1.24 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.27 | $13,100,000 | 1 / 1 |
| 2026-07-25 | $-1.27 | $13,100,000 | 1 / 1 |
| 2026-07-26 | $-1.27 | $13,100,000 | 1 / 1 |
| 2026-07-27 | $-1.27 | $13,100,000 | 1 / 1 |
| 2026-07-28 | $-1.27 | $13,100,000 | 1 / 1 |
| 2026-07-29 | $-1.27 | $13,100,000 | 1 / 1 |
| 2026-07-30 | $-1.27 | $13,100,000 | 1 / 1 |
| 2026-07-31 | $-1.98 | $0 | 1 / 2 |
| 2026-08-01 | $-1.27 | $13,100,000 | 1 / 1 |
| 2026-08-02 | $-1.98 | $0 | 1 / 2 |
| 2026-08-03 | $-1.27 | $13,100,000 | 1 / 1 |
| 2026-08-04 | $-1.98 | $0 | 1 / 2 |
| 2026-08-05 | $-1.98 | $0 | 1 / 2 |
| 2026-08-06 | $-1.98 | $0 | 1 / 2 |
| 2026-08-08 | $-1.27 | $13,100,000 | 1 / 1 |
| 2026-08-09 | $-1.98 | $0 | 1 / 2 |
| 2026-08-10 | $-1.27 | $13,100,000 | 1 / 1 |
| 2026-08-12 | $-1.27 | $13,100,000 | 1 / 1 |
| 2026-08-13 | $-1.98 | $0 | 1 / 2 |
| 2026-08-14 | $-1.27 | $13,100,000 | 1 / 1 |
| 2026-08-15 | $-1.27 | $13,100,000 | 1 / 1 |
| 2026-08-16 | $-1.27 | $13,100,000 | 1 / 1 |
| 2026-08-17 | $-1.27 | $13,100,000 | 1 / 1 |
| 2026-08-18 | $-1.27 | $13,100,000 | 1 / 1 |
| 2026-08-19 | $-1.27 | $13,100,000 | 1 / 1 |
| 2026-08-20 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-08-21 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-08-22 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-08-23 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-08-24 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-08-25 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-08-26 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-08-27 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-08-28 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-08-29 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-08-30 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-08-31 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-09-01 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-09-02 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-09-03 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-09-04 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-09-05 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-09-06 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-09-07 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-09-08 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-09-09 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-09-10 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-09-11 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-09-12 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-09-13 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-09-14 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-09-15 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-09-16 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-09-17 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-09-18 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-09-19 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-09-20 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-09-21 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-09-22 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-09-23 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-09-24 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-09-25 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-09-26 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-09-27 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-09-28 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-09-29 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-09-30 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-10-01 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-10-02 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-10-03 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-10-04 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-10-05 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-10-06 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-10-07 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-10-08 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-10-09 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-10-10 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-10-11 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-10-12 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-10-13 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-10-14 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-10-15 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-10-16 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-10-17 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-10-18 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-10-19 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-10-20 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-10-21 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-10-22 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-10-23 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-10-24 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-10-25 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-10-26 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-10-27 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-10-28 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-10-29 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-10-30 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-10-31 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-11-01 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-11-02 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-11-03 | $-1.24 | $13,100,000 | 1 / 1 |
| 2026-11-04 | $-1.24 | $13,100,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 0 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.